Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Marinus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing neurosteroid-based therapies for rare seizure and neurological disorders. Its flagship product, ZTALMY (ganaxolone), treats seizures associated with Cyclin-dependent Kinase-like 5 Deficiency Disorder (CDD). The company advances clinical programs for other epilepsies, leveraging its expertise in GABAergic modulation, orphan drug designations, and strategic collaborations to address unmet medical needs in neurology.
This description was generated via AI from an annual report. Updated about 1 year ago.